LGALS9 and keratoconus: Our primary aims are to (i) assess the expression of LGALS9 and Tregs in KC mice, (ii) validate the use of a human-specific anti-Galectin-9 on murine Tregs, and subsequently (iii) analyze its influence on LGALS9 expression, Treg infiltration, and, lastly, (iv) PaniN progression in anti-galectin-9-treated KC mice.